MARKET

CDXC

CDXC

ChromaDex
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.975
+0.055
+1.12%
Closed 16:00 08/07 EDT
OPEN
4.940
PREV CLOSE
4.920
HIGH
5.24
LOW
4.800
VOLUME
422.87K
TURNOVER
--
52 WEEK HIGH
5.80
52 WEEK LOW
2.500
MARKET CAP
305.85M
P/E (TTM)
-9.7244
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 4 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average CDXC stock price target is 7.06 with a high estimate of 9.25 and a low estimate of 6.00.

EPS

CDXC News

More
ChromaDex EPS beats by $0.04, beats on revenue
ChromaDex (NASDAQ:CDXC): Q2 GAAP EPS of -$0.06 beats by $0.04. Revenue of $15.3M (+37.8% Y/Y) beats by $1.15M. Press Release
seekingalpha · 3d ago
ChromaDex (CDXC) Reports Q2 Loss, Tops Revenue Estimates
ChromaDex (CDXC) delivered earnings and revenue surprises of 45.45% and 12.71%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 3d ago
ChromaDex Corporation Reports Second Quarter 2020 Financial Results
ChromaDex Corp. (NASDAQ:CDXC) today reported second quarter 2020 financial results.
Business Wire · 3d ago
Will ChromaDex (CDXC) Report Negative Earnings Next Week? What You Should Know
ChromaDex (CDXC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks · 07/30 16:33
ChromaDex to Report Second Quarter 2020 Financial Results on Thursday, August 6, 2020
ChromaDex Corp. (NASDAQ:CDXC) announced that it will hold a conference call on Thurs., August 6, 2020 at 4:30 p.m. ET to discuss its financial results for the second quarter ended Jun. 30, 2020. The financial results will be reported in a press release after t
Business Wire · 07/28 10:32
ChromaDex Highlights Results Of New Preclinical Study Published In 'Nature Scientific Reports' Probing Role Of Niagen In Addressing Social Deficits In Autism Spectrum Disorder
ChromaDex Corp. (NASDAQ:CDXC) today announced the results of a new preclinical study published in Nature Scientific Reports investigating the role of Niagen® (patented nicotinamide riboside) in
Benzinga · 07/16 10:34
New Preclinical Study Finds Niagen® Corrects Social Deficits in Mouse Model of Autism
ChromaDex Corp. (NASDAQ:CDXC) today announced the results of a new preclinical study published in Nature Scientific Reports investigating the role of Niagen® (patented nicotinamide riboside) in addressing social deficits in Autism Spectrum Disorder (ASD). This
Business Wire · 07/16 10:33
ChromaDex External Research Program Signs 200th Material Transfer Agreement For Niagen Research
ChromaDex R&D program continues to pioneer NAD+ and Niagen® research and inks over 200 external research collaborations LOS ANGELES--(BUSINESS WIRE)-- ChromaDex Corp. (NASDAQ:CDXC) today announced the Company
Benzinga · 07/14 10:33

Industry

Biotechnology & Medical Research
-0.18%
Pharmaceuticals & Medical Research
+0.08%

Hot Stocks

Symbol
Price
%Change

About CDXC

Chromadex Corporation is an integrated nutraceutical company. The Company and its subsidiaries ChromaDex, Inc., ChromaDex Analytics, Inc. and Spherix Consulting, Inc. provides research and quality-control products and services to the natural products industry. The Company partners with universities and research institutions worldwide to discover, develop and create solutions to deliver the full potential of nicotinamide adenine dinucleotide (NAD) and its impact on human health. The Company’s operated segments are: Consumer Product, Ingredients, and Analytical Reference Standards and Service Segment. Its Consumer Product segment offers TRU NIAGEN to consumers worldwide. Its ingredients business segment develops and commercializes ingredients, including nicotinamide riboside (NR), for which its brand name is NIAGEN. It also develops pterostilbene, which is marketed and sold under its brand name, pTeroPure.
More

Webull offers kinds of Chromadex Corp stock information, including NASDAQ:CDXC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CDXC stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CDXC stock methods without spending real money on the virtual paper trading platform.